No Data
Yahong Medical (688176.SH) approximately 6.8005 million restricted shares will be listed and circulated starting from January 7.
Yahong Pharmaceutical (688176.SH) announced that the restricted shares for this listing circulation are from the company's initial public offering prior to...
Asia Rainbow Pharmaceuticals (688176.SH): Shareholder voluntarily commits to extend the lock-up period of shares.
Glory Holdings reported on December 27 that Yahon Pharmaceutical (688176.SH) announced that it recently received a commitment letter from the company's Shareholders regarding the voluntary extension of the lock-up period for restricted shares. Based on confidence in the company's future development prospects and recognition of its investment value, the company's controlling Shareholder and actual controller Mr. PANKE's concerted actors, Pan-Scientific Holdings Co., Ltd., Taizhou Donghong Enterprise Management Center (Limited Partnership), and Taizhou Yahon Enterprise Management Center (Limited Partnership), a total of three Shareholders, committed to lock up all the shares they Hold prior to the company's initial public offering.
Jiangsu Yahong Meditech Co., Ltd.'s (SHSE:688176) Intrinsic Value Is Potentially 88% Above Its Share Price
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Report for the Third Quarter of 2024
Yahong Pharmaceuticals accumulated revenue of 0.139 billion yuan in the first three quarters of this year, with two commercialized products continuing to ramp up production.
On the evening of October 29, YAHONG PHARMACEUTICAL (688176.SH) disclosed its third quarter report. The company achieved revenue of 58.4582 million yuan in the third quarter, a year-on-year increase of 1903.16%; for the first three quarters, the cumulative revenue was 0.139 billion yuan, a year-on-year increase of 4537.79%. The revenue growth is mainly attributed to the company starting to sell its drug Pipatinib Tablets (brand name: Dipatte) and Nilotinib Maleate Tablets (brand name: Ouyoubi) in the fourth quarter of 2023. Commercial promotion has steadily progressed during this reporting period, leading to an increase in sales volume.
Yahong Pharmaceutical (688176.SH): The clinical trial application for APL-2302 has been approved by the FDA.
YAHONG Pharmaceuticals (688176.SH) announced that the company has received a notice from the Food and Drug Administration (referred to as the “FDA…
No Data
